German biotechnology company Evotec SE said on Monday that progress had been made within its strategic partnership with US pharmaceutical firm Bristol Myers Squibb. Evotec said it has received a $25 million payment to progress further research. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. A Phase II study for BMS-986419 is scheduled to commence in 2024. The companies entered their strategic neuroscience collaboration in December 2016. In March 2023, the companies extended and expanded the partnership for an additional eight years. Cord Do…